Black Diamond Therapeutics (BDTX) Total Current Liabilities (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Total Current Liabilities came in at $14.5 million in Q1 2026, down 13.73% YoY from $16.8 million in Q1 2025, and down 7.61% on a QoQ basis from $15.7 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Total Current Liabilities (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Total Current Liabilities data on file, last reported at $14.5 million in Q1 2026.
- Quarterly Total Current Liabilities fell 13.73% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.5 million (down 13.73% YoY) and the FY2025 annual result came in at $15.7 million, down 23.54% from the prior year.
- Total Current Liabilities slipped to $14.5 million in Q1 2026, from $15.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $21.1 million in Q3 2022 to a low of $12.8 million in Q1 2023.
- A 5-year average of $17.2 million and a median of $16.8 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 35.45% — and 2024, when it surged 38.06%.
- Tracing BDTX's Total Current Liabilities over 5 years: stood at $15.3 million in 2022, then grew by 28.73% to $19.6 million in 2023, then climbed by 4.72% to $20.6 million in 2024, then fell by 23.54% to $15.7 million in 2025, then decreased by 7.61% to $14.5 million in 2026.
- The last three Total Current Liabilities figures came in at $14.5 million (Q1 2026), $15.7 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 15.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.84 Mn |
| Mar 31, 2026 | 14.53 Mn |
| Dec 31, 2025 | 15.73 Mn |
| Sep 30, 2025 | 15.55 Mn |
| Jun 30, 2025 | 16.81 Mn |
| Mar 31, 2025 | 16.85 Mn |
| Dec 31, 2024 | 20.57 Mn |
| Sep 30, 2024 | 20.80 Mn |
| Jun 30, 2024 | 18.44 Mn |
| Mar 31, 2024 | 16.85 Mn |
| Dec 31, 2023 | 19.65 Mn |
| Sep 30, 2023 | 15.07 Mn |
| Jun 30, 2023 | 13.90 Mn |
| Mar 31, 2023 | 12.85 Mn |
| Dec 31, 2022 | 15.26 Mn |
| Sep 30, 2022 | 21.14 Mn |
| Jun 30, 2022 | 19.71 Mn |
| Mar 31, 2022 | 19.47 Mn |
| Dec 31, 2021 | 23.64 Mn |
| Sep 30, 2021 | 26.36 Mn |